title: Treatment of Kaposi's sarcoma after solid organ transplantation.
abstract: OBJECTIVE
  This retrospective review of all patients who developed Kaposi's sarcoma (KS) after solid organ transplantation at a single institution was undertaken to define the clinical presentation of this malignancy in the setting of iatrogenic immunodeficiency, and to determine the most appropriate treatment for patients in this clinical setting.
  
  
  METHODS
  The records of 2,099 patients who underwent heart, lung, liver, or kidney transplantation at The Toronto Hospital between January 1, 1981 and June 30, 1995, were reviewed. Twelve patients were identified who developed biopsy-proven KS in the posttransplantation period. Five patients who had disseminated KS who had not responded to either reduction or withdrawal of immunosuppression or to local radiotherapy were treated with combination chemotherapy consisting of doxorubicin 20 to 30 mg/m2, bleomycin 10 mg/m2, and vincristine 2 mg (ABV) administered intravenously every 3 weeks.
  
  
  RESULTS
  Eight of 12 patients were male and nine were of Italian origin. KS was limited to a localized area of the skin for only six patients, all after kidney transplantation. Visceral KS was present in three patients. Four of five patients responded to ABV chemotherapy (two complete and two partial remissions). The fifth patient responded to second-line etoposide and cisplatin. The median duration of response was in excess of 13 months (range, 8+ to 45+ months). Toxicity was limited to grade 1 neurotoxicity and grade 1 skin toxicity.
  
  
  CONCLUSIONS
  KS is an uncommon but recognized complication of solid organ transplantation. Combination chemotherapy is a safe and effective treatment for patients with disseminated or visceral KS that fails to respond to changes in immunosuppression.
authors.affiliation: Department of Medicine, The Multi-Organ Transplant Program of The Toronto Hospital, University of Toronto, Ontario, Canada. fshepherd@torhosp.toronto.on.ca
authors.forename: F A
authors.initials: FA
authors.lastname: Shepherd
authors.forename: E
authors.initials: E
authors.lastname: Maher
authors.forename: C
authors.initials: C
authors.lastname: Cardella
authors.forename: E
authors.initials: E
authors.lastname: Cole
authors.forename: P
authors.initials: P
authors.lastname: Greig
authors.forename: J A
authors.initials: JA
authors.lastname: Wade
authors.forename: G
authors.initials: G
authors.lastname: Levy
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006084:Graft Rejection; D006801:Humans; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000009:adverse effects*; D012189:Retrospective Studies; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000208:ethnology / Q000209:etiology; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014747:Vinblastine; D004317:Doxorubicin